Feb 2 |
Nasdaq Rises Over 200 Points; Apple Posts Upbeat Earnings
|
Feb 2 |
Tyra Biosciences spikes on $200M private financing
|
Feb 2 |
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
|
Feb 1 |
Tyra gets FDA Rare Pediatric Disease status for dwarfism drug
|
Feb 1 |
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
|
Dec 29 |
16 Most Promising Long-Term Stocks According to Analysts
|
Dec 22 |
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
|
Nov 8 |
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
|
Nov 8 |
Tyra Biosciences GAAP EPS of -$0.49 misses by $0.14
|
Nov 7 |
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
|